What is the primary driver of Eli Lilly's recent sales growth?

The primary drivers of Eli Lilly's recent sales growth are strong performances from its key products, particularly Zyprexa, diabetes care products like Humulin and Humalog, Gemzar, and Evista. These drugs have shown significant year-over-year increases in sales, contributing substantially to the company's overall revenue.

What is the expected impact of the Prozac patent litigation on the company's future sales?

The company anticipates a very substantial decline in Prozac sales in the U.S. over the next 12 months following the launch of generic fluoxetine in early August 2001. Prozac represented approximately 19% of consolidated worldwide sales in the second quarter of 2001. While this is a significant concern, the company believes it will not have a material adverse effect on its consolidated financial position or liquidity, though it is seeking Supreme Court review of the patent ruling.

How is Eli Lilly managing its manufacturing quality and compliance issues?

Eli Lilly is implementing comprehensive, company-wide improvements in its manufacturing quality operations to ensure sustained compliance with current Good Manufacturing Practices (cGMP) regulations, following observations from recent FDA inspections. The company is working closely with the FDA and providing support to its third-party manufacturers to address these issues, and does not currently expect a material financial impact.

What is Eli Lilly's financial outlook for the remainder of 2001?

Excluding unusual items, Eli Lilly expects full-year 2001 earnings per share to be in the range of $2.76 to $2.84. For the third and fourth quarters of 2001, earnings per share are projected to be between $0.63 and $0.67. The company anticipates a flat to slightly positive gross margin for the year and expects marketing and administrative expenses to rise in the high single digits, while R&D expenses increase in the low double digits.

LLY 10-Q Quarterly Report Q2 FY2001 — Revenue, Net Income, EPS

Summary

Eli Lilly and Company reported strong financial performance for the second quarter and first six months of 2001, demonstrating significant year-over-year growth in net sales and net income. The company's revenue increase was primarily driven by robust sales of key products such as Zyprexa, diabetes care products (Humulin, Humalog, Actos), Gemzar, and Evista. This growth was partially offset by declining sales in the anti-infectives category. Despite facing patent litigation for its flagship product Prozac, which is expected to lead to a substantial decline in U.S. sales following the entry of generic competition, Lilly remains optimistic about its overall financial position and liquidity, planning to seek Supreme Court review of the adverse patent ruling. The company is also managing manufacturing quality improvements and reviewing its global manufacturing capacity. Financially, Lilly saw increased gross margins due to a favorable product mix and managed operating expenses effectively, with R&D and marketing spending growing at a rate below sales growth. The company's cash position remains strong, supported by operating cash flows, though investing activities, particularly in long-term investments, and share repurchases have utilized significant cash. Lilly's financial outlook for the full year 2001 projects earnings per share in the range of $2.76 to $2.84, indicating continued profitability despite the anticipated impact of generic Prozac entry.

Key Highlights

1Net sales increased by 16% to $3.03 billion for Q2 2001 and by 15% to $5.84 billion for the first six months of 2001, compared to the prior year periods.
2Net income grew by 24% to $827.7 million for Q2 2001 and by 20% to $1.63 billion for the first six months of 2001 (excluding unusual items from 2000).
3Earnings per share (diluted) rose to $0.76 for Q2 2001 and $1.50 for the first six months of 2001.
4Key growth drivers included strong performance from Zyprexa (up 34% in Q2), diabetes care products (up 28% in Q2), Gemzar (up 49% in Q2), and Evista (up 25% in Q2).
5Prozac and Sarafem combined sales showed modest growth of 10% in Q2 2001, but the company anticipates a substantial decline due to the loss of market exclusivity following the entry of generic fluoxetine in early August 2001.
6The company is actively engaged in litigation regarding patents for Prozac and Zyprexa, with an unfavorable outcome for Zyprexa patents potentially having a material adverse impact.
7Cash, cash equivalents, and short-term investments stood at $3.50 billion as of June 30, 2001, with $1.55 billion generated from operating activities in the first six months.

ELI LILLY & Co Quarterly Report for Q2 Ended Jun 30, 2001

Summary

Key Highlights

Frequently Asked Questions